Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
18,309
Total Claims
$1.3M
Drug Cost
690
Beneficiaries
$1,924
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+36%
Cost per patient vs peers
$1,924 vs $1,411 avg
+17%
Brand preference vs peers
12.4% vs 10.6% avg
Brand vs Generic
Brand: 2,241 claims · $1.0M
Generic: 15,805 claims · $301K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Rivaroxaban | 142 | $121K |
| Dapagliflozin Propanediol | 137 | $119K |
| Apixaban | 118 | $115K |
| Empagliflozin | 98 | $97K |
| Linagliptin | 67 | $66K |
| Empagliflozin/Metformin Hcl | 60 | $64K |
| Sitagliptin Phosphate | 49 | $57K |
| Insulin Nph Human Isophane | 179 | $43K |
| Insulin Glargine,hum.Rec.Anlog | 82 | $40K |
| Insulin Lispro | 66 | $34K |
| Levothyroxine Sodium | 314 | $30K |
| Insulin Nph Hum/Reg Insulin Hm | 68 | $24K |
| Empaglifloz/Linaglip/Metformin | 31 | $24K |
| Atorvastatin Calcium | 1,709 | $20K |
| Candesartan/Hydrochlorothiazid | 97 | $20K |
Prescribing Profile
Patient Profile
76
Avg Age
60%
Female
1.89
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data